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Summary  Atrial  ﬁbrillation  (AF)  confers  a  substantial  risk  of  stroke.  Recent  trials  compar-
ing vitamin  K  antagonists  (VKAs)  with  non-vitamin  K  antagonist  oral  anticoagulants  (NOACs)  in
AF were  performed  among  patients  with  so-called  ‘‘non-valvular’’  AF.  The  distinction  between
‘‘valvular’’  and  ‘‘non-valvular’’  AF  remains  a  matter  of  debate.  Currently,  ‘‘valvular  AF’’  refers
to patients  with  mitral  stenosis  or  artiﬁcial  heart  valves  (and  valve  repair  in  North  American
guidelines  only),  and  should  be  treated  with  VKAs.  Valvular  heart  diseases,  such  as  mitral  regur-
gitation,  aortic  stenosis  (AS)  and  aortic  insufﬁciency,  do  not  result  in  conditions  of  low  ﬂow  in
the left  atrium,  and  do  not  apparently  increase  the  risk  of  thromboembolism  brought  by  AF.
Post-hoc analyses  suggest  that  these  conditions  probably  do  not  make  the  thromboembolic  risk
less responsive  to  NOACs  compared  with  most  forms  of  ‘‘non-valvular’’  AF.  The  pathogenesis
of thrombosis  is  probably  different  for  blood  coming  into  contact  with  a  mechanical  prosthetic
valve compared  with  what  occurs  in  most  other  forms  of  AF.  This  may  explain  the  results  of  the
only trial  performed  with  a  NOAC  in  patients  with  a  mechanical  prosthetic  valve  (only  a  few
of whom  had  AF),  where  warfarin  was  more  effective  and  safer  than  dabigatran.  By  contrast,
AF in  the  presence  of  a  bioprosthetic  heart  valve  or  after  valve  repair  appears  to  have  a  risk
of thromboembolism  that  is  not  markedly  different  from  other  forms  of  ‘‘non-valvular’’  AF.
Obviously,  we  should  no  longer  consider  the  classiﬁcation  of  AF  as  ‘‘valvular’’  (or  not)  for  the
purpose of  deﬁning  the  aetiology  of  the  arrhythmia,  but  for  the  determination  of  a  different
risk of  thromboembolic  events  and  the  need  for  a  speciﬁc  antithrombotic  strategy.  As  long  as
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there  is  no  better  new  term  or  widely  accepted  deﬁnition,  ‘‘valvular  AF’’  refers  to  patients
with mitral  stenosis  or  artiﬁcial  heart  valves.  Patients  with  ‘‘non-valvular  AF’’  may  have  other
types of  valvular  heart  disease.  One  should  emphasize  that  ‘‘non-valvular  AF’’  does  not  exclude
patients with  some  types  of  valvular  heart  disease  from  therapy  with  NOACs.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  ﬁbrillation  atriale  (FA)  est  associée  à  un  risque  d’accident  vasculaire  cérébral.  Les
essais récents  comparant  antivitamines  K  (AVK)  et  anticoagulants  oraux  directs  non-AVK  (NACO)
dans la  FA  ont  été  réalisés  chez  des  patients  avec  FA,  dite  « non  valvulaire  ».  La  différence  entre
FA « valvulaire  » et  « non  valvulaire  » reste  néanmoins  sujet  à  controverses.  Actuellement,  la  FA
« valvulaire  » fait  référence  aux  patients  avec  rétrécissement  mitral  ou  prothèse  valvulaire  car-
diaque (ainsi  qu’aux  plasties  mitrales  dans  les  recommandations  nord  américaine)  et  nécessite
un traitement  par  AVK.  Les  valvulopathies,  telles  que  l’insufﬁsance  mitrale,  le  rétrécissement
aortique  ou  l’insufﬁsance  aortique  ne  sont  pas  associées  à  un  bas  débit  dans  l’oreillette  gauche
et semblent  ne  pas  augmenter  le  risque  thromboembolique  lié  à  la  FA.  Des  analyses  post-hoc
suggèrent que  le  bénéﬁce  des  NACO  dans  ces  pathologies  n’est  pas  différent  de  celui  constaté
pour les  autres  patients  avec  FA  « non  valvulaire  ».  Le  processus  de  thrombogénicité  est  prob-
ablement  différent  des  autres  formes  de  FA  lorsque  le  sang  entre  en  contact  avec  du  matériel
de prothèse  valvulaire  mécanique.  Ceci  pourrait  expliquer  les  résultats  négatifs  du  seul  essai
réalisé à  ce  jour  avec  un  NACO  chez  des  patients  avec  prothèses  mécaniques  (dont  seulement
une minorité  avaient  de  la  FA)  et  où  la  warfarine  à  été  plus  efﬁcace  et  plus  sûre  que  le  dabi-
gatran. En  revanche,  la  FA  chez  des  patients  avec  une  bioprothèse  ou  une  plastie  valvulaire
semble associée  à  un  risque  thromboembolique  assez  similaire  à  celui  attendu  pour  une  FA
« non  valvulaire  ».  Manifestement,  il  ne  faut  plus  envisager  la  classiﬁcation  d’une  FA  comme
« valvulaire  » (ou  « non  valvulaire  »)  pour  déﬁnir  l’étiologie  de  l’arythmie,  mais  dans  le  but  de
déterminer  un  risque  différent  d’évènements  thromboemboliques  et  pour  établir  un  traitement
antithrombotique  spéciﬁque.  Tant  qu’il  n’y  aura  pas  de  meilleur  terme  ou  de  nouvelle  déﬁnition
largement  acceptée,  la  FA  « valvulaire  » fait  référence  aux  patients  avec  rétrécissement  mitral
ou avec  prothèse  valvulaire  (mécanique  ou  biologique).  Les  patients  avec  FA  « non  valvulaire  »
peuvent avoir  d’autres  types  de  valvulopathies.  Il  faut  donc  insister  sur  le  fait  que  la  déﬁnition
de FA  « non  valvulaire  » n’exclut  pas  certains  patients  avec  valvulopathies  des  possibilités  de
traitement  par  NACO.
©  2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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associated  with  AF  in  the  presence  of  the  various  valve  dis-Background
Atrial  ﬁbrillation  (AF)  is  the  most  common  arrhythmia,
and  confers  a  substantial  risk  of  stroke.  In  the  absence  of
anticoagulation,  thromboembolic  risk  ranges  from  <  1%  per
year  —  similar  to  the  background  risk  of  the  age-matched
population  —  to  >  20%  per  year.  The  risk  of  stroke  and  sys-
temic  embolism  in  AF  may  be  assessed  by  simple  clinical
risk  factors  and  scoring  systems  [1].  This  has  led  to  the  wide
use  of  oral  anticoagulation  as  a  preventive  strategy  for  most
patients  with  AF,  unless  clearly  at  very  low  risk  [1,2]. The
recent  availability  of  non-vitamin  K  antagonist  oral  anticoag-
ulants  (NOACs)  is  likely  to  increase  the  number  of  AF  patients
efﬁciently  treated  for  stroke  prevention.  Recent  trials  com-
paring  vitamin  K  antagonists  (VKAs)  with  NOACs  in  AF  were
performed  among  patients  with  so-called  ‘‘non-valvular’’
AF,  and  excluded  patients  at  high  risk  of  thromboembolism,
e
c
cuch  as  those  with  AF  accompanying  mitral  stenosis  or  with
echanical  prosthetic  valves.  Beyond  the  higher  risk  of
troke  and  ethical  issues  in  the  clinical  development  of
OACs,  a  reason  for  excluding  these  patients  in  trials  testing
OACs  was  the  possibility  that  the  pathogenesis  of  throm-
oembolism  may  be  substantially  different  from  that  in
ther  AF  patients.  The  distinction  between  ‘‘valvular’’  AF
nd  ‘‘non-valvular’’  AF  still  remains  a matter  of  debate,
owever,  with  different  designations  adopted  in  the  liter-
ture.
We  discuss  the  deﬁnitions  of  the  terms  ‘‘valvular’’  and
‘non-valvular’’  AF  in  different  trials  with  NOACs  and  in  cur-
ent  guidelines.  We  also  review  the  thromboembolic  riskases,  and  the  qualitative  type  of  possible  thrombus  in  such
onditions.  All  of  these  factors  may  have  implications  for
linical  practice  and  future  investigations.
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iffering deﬁnitions of ‘‘valvular atrial
brillation’’
rials of thromboprophylaxis in atrial
brillation
he  issue  of  ‘‘valvular  AF’’  deﬁnition  is  relevant  because
ost  of  these  patients  were  excluded  from  recent  trials
esting  NOACs  in  patients  with  AF  [3—19]. Consequently,
OACs  have  been  registered  and  are  currently  indicated  only
or  patients  with  so-called  ‘‘non-valvular  AF’’.  The  reasons
or  excluding  patients  with  ‘‘valvular  AF’’  included  uncer-
ainties  about  whether  the  mechanism  of  thrombogenesis
n  such  patients  is  similar  to  that  occurring  in  the  more
ommon  forms  of  ‘‘non-valvular’’  AF  and,  consequently,
hether  a  similar  anticoagulation  strategy  is  appropriate.
he  criteria  for  excluding  such  patients  were,  however,  vari-
ble  (Table  1).  In  the  RE-LY  trial  testing  dabigatran  versus
arfarin,  ‘‘history  of  heart  valve  disorders’’  was  an  exclu-
ion  criterion,  and  the  disorders  were  deﬁned  as  prosthetic
alve  or  haemodynamically  relevant  valve  disease,  resulting
n  the  exclusion  of  patients  with  AF  and  severe  mitral  or
ortic  insufﬁciency  or  severe  AS  [6].
The  ROCKET-AF  trial,  evaluating  rivaroxaban  against  war-
arin,  excluded  only  haemodynamically  signiﬁcant  mitral
alve  stenosis  and  prosthetic  heart  valves,  but  permitted  the
nclusion  of  patients  with  other  diseases  in  native  valves,  as
ell  as  patients  treated  with  annuloplasty,  commisurotomy
r  valvuloplasty  [17].
In  ARISTOTLE,  evaluating  apixaban  versus  warfarin,
atients  with  ‘‘clinically  signiﬁcant  (moderate  or  severe)
itral  stenosis’’,  as  well  as  ‘‘onditions  other  than  AF  that
equire  chronic  anticoagulation  (e.g.  prosthetic  mechanical
eart  valve)’’  were  excluded,  therefore  allowing  the  inclu-
ion  of  patients  with  native  valvular  heart  disease  other  than
itral  stenosis  and  bioprosthetic  heart  valves  [11].
In  the  AVERROES  trial,  evaluating  apixaban  versus  aspirin
n  patients  considered  ‘‘unsuitable’’  for  VKAs,  ‘‘valvular  dis-
ase  requiring  surgery’’  was  among  the  exclusion  criteria
nd  ‘‘unsuitability’’  for  VKAs  thus  excluded  patients  with
echanical  prosthetic  valves  [5].
In  the  last  trial,  the  ENGAGE-AF  study,  which  tested
wo  strategies  of  edoxaban  versus  warfarin,  patients  with
‘moderate  or  severe  mitral  stenosis  or  a  mechanical  heart
alve’’  were  excluded,  while  the  inclusion  of  patients  with
ioprosthetic  heart  valves  and/or  valve  repair  was  permit-
ed  [10].
After  the  publication  of  the  main  trial  results,  some
ubanalyses  are  now  addressing  the  outcomes  of  patients
ncluded  with  some  sort  of  valvular  heart  disease,  but  only
 few  speciﬁc  subgroup  analyses  of  patients  with  ‘‘valvular
eart  disease’’  have  been  reported.
In  a  subgroup  analysis  of  RE-LY  in  patients  with  symp-
omatic  heart  failure,  1283  (26%)  of  the  patients  with  heart
ailure  and  2661  (20%)  of  the  patients  without  heart  failure
ad  some  sort  of  ‘‘valvular  heart  disease’’,  but  no  informa-
ion  on  outcomes  is  currently  available  for  these  patients
20].
The  most  detailed  information  comes  from  a  secondary
nalysis  of  ROCKET-AF,  which  included  14,171  AF  patients,
4%  of  whom  had  ‘‘signiﬁcant’’  valvular  disease,  some  with
f
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oL.  Fauchier  et  al.
ombined  lesions  [21]. Mitral  regurgitation  was  by  far  the
ost  frequent  valve  disease,  seen  in  90%  of  the  patients,
hile  only  11%  had  AS.  The  authors  raised  the  point  that
any  patients  with  ‘‘non-valvular  AF’’  have  signiﬁcant  valve
esions,  and  this  is  likely  to  be  even  more  common  in
atients  seen  outside  the  context  of  a  randomized  trial.  The
isk  of  stroke  in  those  with  ‘‘signiﬁcant’’  valvular  disease
as  found  to  be  similar  to  that  in  patients  without  signiﬁ-
ant  valve  disease  after  controlling  for  stroke  risk  factors.
ombined  efﬁcacy  endpoints  in  patients  with  and  without
alvular  disease  were  similar  in  patients  treated  with  war-
arin  or  rivaroxaban.  Bleeding  outcomes  were  similar  in
hose  without  valvular  disease,  but  were  more  frequent
ith  rivaroxaban  than  warfarin  in  valvular  disease  patients.
ntracranial  bleeding  was  signiﬁcantly  reduced  by  rivarox-
ban  in  patients  with  no  valvular  disease,  and  was  also
educed,  albeit  not  signiﬁcantly,  in  valvular  disease  patients
non-signiﬁcant  interaction).  Whether  this  effect  is  real  or
imply  the  result  of  multiple  post-hoc  analyses  of  the  data  is
ebatable.  Anyway,  the  authors  concluded  that  AF  patients
ith  and  without  valve  disease  experience  the  same  stroke
reventive  beneﬁt  from  oral  anticoagulants.
In  a  subanalysis  of  ARISTOTLE,  which  has  only  been
eported  in  preliminary  form,  4808  (26%)  of  the  enrolled
atients  had  ‘‘at  least  moderate’’  heart  valve  disease  [22].
he  results  of  this  subanalysis  were  consistent  with  those
f  the  overall  ARISTOTLE  trial,  with  no  signiﬁcant  interac-
ion  according  to  the  presence  or  absence  of  valvular  heart
isease  for  both  stroke  and  systemic  embolism  and  major
leeding.
In  summary,  exclusion  criteria  for  concomitant  valve  dis-
ase  varied  slightly  in  pivotal  trials  with  NOACs  for  stroke
revention  in  AF,  with  exclusion  of  most  valvular  disease
atients  implemented  in  some  studies,  while  others  included
ome  patients  with  non-rheumatic  valvular  disease,  valve
epair  or  bioprostheses.  However,  a  general  term  of  ‘‘non-
alvular  AF’’  was  used  for  the  labelling  of  NOACs,  because
 clinician  cannot  refer  to  the  speciﬁc  inclusion  criteria
f  each  trial  before  prescribing  an  NOAC,  which  were  not
idely  available  at  the  same  time  in  all  countries.  In  recent
ears,  this  has  led  the  scientiﬁc  societies  to  redeﬁne  more
recisely  which  patients  with  AF  may  be  considered  to  have
‘valvular’’  and  ‘‘non-valvular’’  AF.
uidelines
n  addition  to  the  lack  of  absolute  consistency  reported
bove,  the  deﬁnitions  of  ‘‘valvular’’  and  ‘‘non-valvular’’  AF
lso  differ  slightly  in  the  various  guidelines.  In  2008,  the
merican  College  of  Chest  Physicians  guidelines  proposed
ecommendations  for  patients  with  valvular  heart  disease
nd  AF,  including  mitral  stenosis  and  prosthetic  heart  valves
23]; no  speciﬁc  change  to  the  deﬁnition  was  made  in  the  lat-
st  edition  of  these  guidelines,  published  in  2012  [24].  The
012  focused  update  of  the  European  Society  of  Cardiology
ESC)  guidelines  on  AF  indicated  that  it  is  ‘‘conventional’’
o  divide  AF  into  cases  that  are  described  as  ‘‘valvular’’  or
‘non-valvular’’.  Although  stating  that  no  satisfactory  or  uni-
orm  deﬁnition  of  these  terms  exists,  the  term  ‘‘valvular
F’’  used  in  this  guideline  implied  that  AF  was  ‘‘related  to
heumatic  valvular  disease  (predominantly  mitral  stenosis)
r  prosthetic  heart  valves’’  [1]. The  2011  American  Heart
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Table  1  Exclusion  criteria  related  to  valve  disease  in  phase  II  and  III  trials  with  the  new  anticoagulants  in  atrial
ﬁbrillation.
Study  drug  Study  acronym/name  Year  of  publication  Atrial  ﬁbrillation  exclusion  criteria
related  to  valve  disease
Apixaban  AVERROES  [5,7]  2011  Valvular  disease  requiring  surgery,
prosthetic  mechanical  heart  valve
Apixaban  ARISTOTLE  [11,14]  2011  Clinically  signiﬁcant  (moderate  or
severe)  mitral  stenosis,  prosthetic
mechanical  heart  valve
Apixaban  ARISTOTLE-J  [15]  2011  Valvular  heart  disease
Betrixaban  EXPLORE-Xa  [4]  2013  Prosthetic  mechanical  heart  valve
Dabigatran  PETRO  [9]  2007  Mitral  stenosis,  prosthetic  valves
Dabigatran  RE-LY  [6,8]  2009  History  of  heart  valve  disorder  (including
haemodynamically  relevant  valve  disease
and  prosthetic  valve)
Edoxaban  Edoxaban  phase  II  study  [19]  2012  Comorbid  rheumatic  valvular  disease,
history  of  valvular  surgery,  infective
endocarditis
Edoxaban  ENGAGE-AF-TIMI  48  [10,18]  2013  Moderate  or  severe  mitral  stenosis,
unresected  atrial  myxoma,  mechanical
heart  valve
Rivaroxaban  ROCKET-AF  [17]  2011  Haemodynamically  signiﬁcant  mitral
valve  stenosis,  prosthetic  heart  valve
Rivaroxaban  J-ROCKET-AF  [13]  2012  Haemodynamically  signiﬁcant  mitral
valve  stenosis,  prosthetic  heart  valve
Ximelagatran  SPORTIF  III  [12,16]  2003  Mitral  stenosis,  previous  valvular  heart
surgery,  active  infective  endocarditis
Ximelagatran  SPORTIF  V  [3,12]  2005  Mitral  stenosis,  previous  valvular  heart
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Society  AF  guidelines  said  that:  ‘‘the  historical  term  ‘non-
valvular  AF’  is  restricted  to  cases  in  which  the  rhythm
disturbance  occurs  in  the  absence  of  rheumatic  mitral  valve
disease,  a  prosthetic  heart  valve  or  mitral  valve  repair’’
[25].  This  was  conﬁrmed  in  the  2014  update,  where  non-
valvular  AF  was  deﬁned  as  AF  in  the  absence  of  rheumatic
mitral  stenosis,  a  mechanical  or  bioprosthetic  heart  valve  or
mitral  valve  repair  [26].
Overall,  the  main  scientiﬁc  societies  agree  that  patients
with  mitral  rheumatic  valve  disease  or  a  prosthetic  valve
(whether  mechanical  or  biological)  have  ‘‘valvular  AF’’,  but
there  are  disagreements,  mainly  regarding  patients  with
valve  repair  and  possibly  those  with  AF  and  rheumatic  valve
disease  not  located  at  the  mitral  valve.
Valve diseases, atrial ﬁbrillation and the
risk  of stroke
The  discrepancies  mentioned  above  raise  the  question  of
whether  the  mechanisms  of  thrombogenesis  and  throm-
boembolic  risks  might  vary  in  AF  patients  with  various
valve  conditions.  Valvular  heart  disease,  independent  of
the  underlying  cardiac  rhythm,  may  be  associated  with  an
increased  risk  of  thromboembolic  events.  On  the  other  hand,
some  types  of  AF,  such  as  those  accompanying  rheumatic
mitral  stenosis  and  mechanical  prosthetic  valves,  have  long
been  known  to  have  a  high  risk  of  thromboembolism,  and
m
B
e
tsurgery,  active  infective  endocarditis
ave  been  excluded  from  recent  AF  trials  with  NOACs.  There
s  wide  uncertainty,  however,  about  the  possible  different
isks  of  thromboembolism  in  other  forms  of  valvular  disease.
 precise  reappraisal  of  what  is  currently  known  for  each  of
hese  conditions  may  be  needed  for  a  better  understanding
f  the  different  issues,  including  the  risk  of  thromboembolic
vents,  and  the  beneﬁts  and  risks  associated  with  antithrom-
otic  therapy  in  each  setting;  this  will  help  us  to  understand
he  remaining  questions  surrounding  the  current  deﬁnitions
f  ‘‘valvular  AF’’.
ative valve disease
itral stenosis
p  to  80%  of  patients  with  mitral  stenosis  and  systemic
mbolism  have  AF.  Mitral  stenosis  was  estimated  to  be
esponsible  for  25%  of  all  deaths  from  systemic  embolism
hen  surgery  and  anticoagulation  were  not  available  [27].
hile  the  stroke  rate  in  patients  with  AF  is,  on  average,
pproximately  six  times  the  stroke  risk  in  people  without
F,  the  relative  risk  is  about  15  in  patients  who  have  AF
nd  mitral  stenosis  [28].  It  is  controversial  whether  patients
ith  mitral  stenosis,  but  without  AF,  are  at  a  higher  risk
f  embolic  events,  and  there  is  only  a  low-grade  recom-
endation  for  oral  anticoagulants  in  recent  guidelines  [29].
y  contrast,  patients  with  mitral  stenosis  and  AF  who  have
xperienced  an  embolic  event  have  recurrences  at  a  rate
hat  is  the  highest  reported  for  AF  patients.  This  may  be
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elated  to  the  low  ﬂow  occurring  in  the  left  atrium  in  case
f  AF  with  mitral  stenosis.  There  have  been  no  speciﬁc  ran-
omized  trials  evaluating  the  beneﬁt  of  anticoagulation  for
troke  prevention  in  patients  with  mitral  stenosis,  and  cur-
ent  recommendations  are  based  on  retrospective  analysis
howing  a  4-fold  to  15-fold  decrease  in  the  incidence  of
mbolic  events  with  anticoagulation  in  these  patients  [30].
uch  patients  have  not  yet  been  randomized  between  alter-
ative  treatments,  but  there  are  no  clear  reasons  to  suggest
 differential  response  to  various  anticoagulants.
itral regurgitation
he  multiple  mechanisms  of  mitral  regurgitation  with  very
ifferent  patient  proﬁles  may  explain  the  various  ﬁndings
hen  studying  the  prevalence  of  thromboembolism  in  these
atients.  While  some  degree  of  mitral  regurgitation  may
e  associated  with  rheumatic  mitral  stenosis,  which  itself
ubstantially  increases  the  risk  of  thromboembolism  in  AF,
his  may  be  different  in  AF  with  mitral  regurgitation  of  non-
heumatic  aetiology.  There  are  now  some  data  on  the  effect
f  mild  mitral  regurgitation  on  the  occurrence  of  throm-
oembolic  events.
Many  studies  have  suggested  that  the  presence  of  mitral
egurgitation  with  AF  may  have  a  protective  role  in  the
ccurrence  of  thromboembolic  events  [31,32].  In  a  ret-
ospective  study  of  313  AF  patients,  the  incidence  of
hromboembolism  was  signiﬁcantly  higher  in  the  group  with
o  mitral  regurgitation  [33].  Mild  and  moderate  mitral  regur-
itation  might  increase  the  thromboembolic  risk  [34], in
ontrast  to  severe  mitral  regurgitation,  which  might  have
 protective  effect  [35,36].  The  proposed  mechanism  would
e  an  increase  in  atrial  washing  and  emptying,  and  reduced
ntra-atrial  stasis,  but  these  suggestions  remain  controver-
ial.  A  recent  analysis  by  our  group  does  not  allow  ﬁrm
onclusions  to  be  drawn  on  this  point,  although  917  (61%)
f  the  AF  patients  with  valve  disease  had  mitral  regur-
itation,  which  makes  it  one  of  the  largest  reports  on
utcomes  for  such  patients.  Neither  mitral  regurgitation  nor
everity  of  valve  disease  was  associated  with  a  higher  risk
f  stroke/thromboembolic  events  in  multivariable  analysis
37].
The  idea  that  the  occurrence  of  mitral  regurgitation
er  se  does  not  result  in  an  increased  risk  of  stroke  in  AF
as  also  been  supported  by  studies  of  spontaneous  echo
ontrast  on  transoesophageal  echocardiography,  considered
o  be  a  manifestation  of  a  hypercoagulable  state.  Sponta-
eous  echo  contrast  in  the  left  atrium  (LA)  is  more  common
n  patients  with  atrial  arrhythmias,  mitral  stenosis,  mitral
alve  prosthesis  and  enlarged  LA  —  all  conditions  associated
ith  LA  stasis  —  while,  interestingly,  patients  with  severe
itral  regurgitation  may  have  less  frequent  LA  spontaneous
cho  contrast  [35,38].  Similarly,  plasma  d-dimer  levels,
hich  partly  correlate  with  embolic  risk  in  both  mitral  valve
isease  and  non-valvular  AF,  have  been  found  to  be  high-
st  in  patients  with  mitral  stenosis  with  AF  and  non-valvular
F.  d-dimer  levels  were  lower  and  similar  to  control  levels
n  a  small  series  of  patients  with  mitral  stenosis  and/or  AF
ith  severe  mitral  regurgitation  [39,40].  Overall,  one  cannot
rmly  state  that  mitral  regurgitation  is  protective  against
eft  atrial  thrombus  and  systemic  thromboembolism,  but  it
t  least  seems  that  mitral  regurgitation  does  not  increase
s
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he  risk  of  stroke  beyond  the  other  risk  factors  commonly
ound  in  patients  with  such  valve  disease.
Mitral  valve  prolapse  is  a  relatively  common  form  of  valve
isease  occurring  in  1—2.5%  of  the  general  population,  and
arly  case  series  suggested  an  association  with  stroke  [41].
ore  recent  and  relatively  large  reports  did  not  replicate
his  ﬁnding  [42,43]. Mitral  valve  prolapse  may  be  compli-
ated  by  AF,  as  a  consequence  of  mitral  regurgitation  with
ossible  LA  dilatation  and  left  ventricular  enlargement,  but
t  is  uncertain  if  the  combination  of  mitral  valve  prolapse
nd  AF  increases  the  risk  of  stroke  per  se  beyond  the  risk
rought  by  AF  and  the  usual  possibly  associated  risk  factors
n  these  patients  [41].
ther valve disease
S  has  now  became  the  most  common  valvulopathy  in  West-
rn  countries,  and  frequently  co-exists  with  AF,  but  there  are
nly  a  few  reports  in  the  literature  referring  to  the  risk  of
hromboembolism  for  AF  accompanying  AS  and  comparing  it
ith  that  for  AF  with  no  AS.  Thromboembolic  events  related
o  aortic  valve  disease  are  less  common  than  those  associ-
ted  with  a  mitral  disease.  The  precise  physiopathology  of
troke  in  a  patient  with  calciﬁed  AS  is  sometimes  difﬁcult  to
stablish.  In  our  registry,  AS  was  present  in  32%  of  AF  patients
ith  valve  disease  (18%  with  non-severe  AS  and  14%  with
evere  AS)  [37]. These  latter  patients  had  a  higher  risk  of
troke,  but  patients  with  AS  were  older  and  more  frequently
ad  co-morbidities,  and  therefore  had  a  higher  CHA2DS2-
ASc  risk  score;  this  probably  contributed  to  the  increased
isk  of  stroke/thromboembolic  events  for  patients  in  the
roup  with  valve  disease.  In  current  guidelines,  anticoagula-
ion  is  not  indicated  when  there  is  no  AF  [29]. However,  silent
F  might  be  responsible  for  some  thromboembolic  events  in
ddition  to  atherosclerosis  or  calcic  microemboli  in  patients
ith  valve  diseases  [44].
To our  knowledge,  there  is  no  established  relationship
etween  aortic  regurgitation  and  the  risk  of  thromboem-
olic  events  in  patients  with  AF.  In  our  study  mentioned
bove,  this  condition  did  not  seem  to  be  predictive  of
troke/thromboembolic  events  [37]. Finally,  there  is  no  evi-
ence  in  the  literature  for  a  speciﬁc  role  for  tricuspid
egurgitation  in  increasing  the  incidence  of  thromboem-
olism  once  AF  has  occurred.
The  recent  report  from  our  registry  of  the  Loire  Valley
trial  Fibrillation  Project  adds  to  our  general  knowledge
f  patients  with  valve  disease  who,  nevertheless,  meet  the
riteria  of  non-valvular  AF  [37].  Among  8962  patients  seen
n  a cardiology  department,  there  were  10%  with  ‘‘valvular
F’’  as  currently  deﬁned  in  the  ESC  guidelines,  whereas  the
emaining  patients  had  ‘‘non-valvular  AF’’.  These  patients
ere  categorized  into  those  without  any  valve  disease  (85%)
nd  those  with  valve  disease,  but  with  neither  rheumatic
itral  stenosis  nor  valve  prosthesis  (15%).
Patients  with  valve  disease  were  older,  had  a  higher
HA2DS2-VASc  score  and  had  a  higher  risk  of  thromboembolic
vents  than  patients  without  valve  disease.  The  main  ﬁnding
as  that  the  predictive  value  of  the  CHA2DS2-VASc  score  was
imilar  in  both  groups.  As  a  valve  disease  in  non-valvular  AF
as  not  independently  associated  with  an  increased  risk  of
mbolic  events,  the  higher  CHA2DS2-VASc  score  was  likely
o  explain  the  increased  risk  observed  in  these  patients,
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and  should  remain  the  principal  determining  factor  when
deciding  whether  oral  anticoagulation  is  needed  for  stroke
prevention.  In  this  subgroup,  23%  were  considered  to  have
a  severe  valve  disease  based  on  echocardiography  and,  to
date,  very  little  information  is  available  on  the  incidence  of
stroke  in  these  patients.  Importantly,  the  severity  of  valve
disease  in  our  registry  was  not  independently  associated
with  a  higher  risk  of  stroke  or  systemic  embolism.
Therefore,  with  the  remarkable  exception  of  mitral
stenosis,  all  forms  of  native  valvular  heart  disease  accom-
panying  AF  do  not  appear  to  increase  the  risk  of
thromboembolism  beyond  the  level  expected  with  AF  strati-
ﬁed  with  the  CHA2DS2-VASc  score  alone,  and  do  not  actually
act  as  independent  additional  risk  factors.
Valve surgery
Mechanical prostheses
Patients  with  a  mechanical  heart  valve  are  at  risk  of  throm-
boembolism  and  require  chronic  anticoagulation.  A  VKA
is  required  even  for  patients  with  sinus  rhythm,  but  AF
still  enhances  the  risk  of  thromboembolism  [45].  Without
anticoagulation,  the  thromboembolic  risk  may  reach  23%
per  year  with  the  oldest  valves,  but  is  lower  with  new-
generation  valves  [46,47].  The  risk  of  thromboembolism
is  estimated  to  be  4.0%/year  with  no  anticoagulation  in
patients  with  mechanical  valves,  and,  among  them,  those
with  mitral  valve  prostheses  are  at  approximately  twice
the  risk  compared  with  those  with  aortic  valve  prostheses
[46].  Systemic  embolization  and  cerebrovascular  events  are
reduced  to  a  rate  of  0.7—1.0%  per  patient-year  in  patients
with  mechanical  valves  treated  with  warfarin  [48,49]. There
are  several  mechanisms  for  thrombosis  and  thromboem-
bolism  in  patients  with  a  mechanical  prosthetic  valve  and
AF.  Thrombus  may  occur  on  the  prosthesis  and  its  different
elements,  consisting  of  an  initial  layer  of  platelets  and  a
ﬁbrin  network,  and  in  the  left  atrium,  most  often  in  the  left
atrial  appendage,  related  to  ﬂow  disturbances  caused  by  the
prosthesis,  and  mainly  consisting  of  a  ﬁbrin  network  trapping
blood  components.  It  is  likely  that  these  two  mechanisms
vary  in  their  responsiveness  to  current  antithrombotic  drugs
[50].
Patients  with  AF  and  a  mechanical  heart  valve  were  sys-
tematically  excluded  from  all  the  recent  major  trials  with
NOACs,  based  on  the  hypothesis  that  a  speciﬁc  anticoagula-
tion  intensity  may  be  needed  in  such  patients,  and  because
of  the  lack  of  experience.  There  were,  however,  hopes  that
NOACs  could  be  a  valuable  substitute  for  VKAs  in  this  set-
ting.  A  phase  II  dose-validation  study  with  dabigatran  was
performed  in  such  patients.  This  is  the  only  intervention
trial  performed  so  far  with  an  NOAC  in  patients  with  a
mechanical  prosthetic  valve  (only  23%  of  whom  had  AF),  and
included  patients  with  implantation  within  the  past  7  days
of  a  mechanical  bileaﬂet  valve  in  the  aortic  and/or  mitral
position  or  patients  who  had  undergone  implantation  of  a
mechanical  bileaﬂet  mitral  valve  more  than  3  months  before
randomization  [50].  The  initial  dabigatran  dose  (150,  220  or
300  mg  twice  daily)  was  adjusted  to  obtain  a  trough  plasma
concentration  of  at  least  50  ng/mL.  The  primary  endpoint
was  the  trough  plasma  concentration  of  dabigatran.  The
trial  was  terminated  prematurely  after  the  enrolment  of  252
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atients  because  of  an  excess  of  thromboembolic  events  (5%
s.  0%)  and  major  bleeding  events  (4%  vs.  2%)  among  patients
n  the  dabigatran  group,  showing  no  beneﬁt  and  an  excess
isk  compared  with  warfarin  [50].
Differences  in  the  mechanisms  of  action  of  dabigatran
nd  warfarin  may  explain  at  least  some  of  the  ﬁndings.  In
atients  with  a  mechanical  heart  valve,  coagulation  acti-
ation  and  thrombin  generation  induced  by  the  release  of
issue  factor  during  surgery  may  explain  the  higher  risk  of
arly  thromboembolic  complications.  Thrombin  generation
an  also  be  triggered  by  exposure  of  the  blood  to  the  arti-
cial  surface  of  the  valve  leaﬂets  and  sewing  ring,  which
nduces  activation  of  the  contact  pathway  of  coagulation
efore  endothelialization  has  occurred.  Whereas  dabigatran
xclusively  inhibits  thrombin,  VKAs  are  likely  to  be  more
ffective  in  this  early  postoperative  period  because  they
nhibit  the  activation  of  both  tissue  factor-induced  coagu-
ation  (by  inhibiting  the  synthesis  of  coagulation  factor  VII)
nd  contact  pathway-induced  coagulation  (by  inhibiting  the
ynthesis  of  factor  IX),  as  well  as  inhibiting  the  synthesis  of
actor  X  and  thrombin  in  the  common  pathway  [51].  The  neg-
tive  experience  with  dabigatran  has  temporarily  stopped
he  development  of  NOACs  for  such  patients.  Therefore,  at
he  present  time,  patients  with  AF  and  a  mechanical  heart
alve  should  only  be  treated  with  a  VKA.
ioprostheses
ioprostheses  are  considered  to  be  less  thrombogenic  than
echanical  valves,  although  the  incidence  of  valve  thrombo-
is  in  porcine  valves  without  anticoagulation  may  be  close  to
hat  of  mechanical  valves  with  anticoagulation.  Pericardial
alves  were  introduced  in  the  1970s  to  improve  haemody-
amics  and  decrease  the  rate  of  structural  failure,  and  they
ppear  less  at  risk  of  valve  thrombosis  than  porcine  valves
52]. Stentless  bioprosthesis  was  introduced  in  1992  with
he  aim  of  improving  haemodynamic  function  and  increasing
urability  compared  with  stented  tissue  valves  [53].
After  biological  valve  replacement,  thromboembolic  risk
s  estimated  to  be  between  0.6%  and  3.3%  per  year  without
nticoagulation,  after  the  third  month  [45]. Many  guide-
ines  recommend  anticoagulation  with  VKAs  during  the  ﬁrst
 postoperative  months.  This  period  allows  the  endothelial-
zation  of  bioprosthetic  material  [54].  This  recommendation
s  well  established  for  mitral  bioprosthesis  because  of  the
igher  risk  of  postoperative  AF.  Anticoagulation  during  the
rst  3  months  is  more  debatable  for  aortic  bioprostheses,
iven  the  absence  of  high-level  evidence  [55,56]. The  risk
f  bioprostheses  thrombosis  is  increased  by  low  cardiac  out-
ut  and  by  valve  deterioration  with  calciﬁed  surface  [57,58].
he  risk  of  embolization  is  more  important  in  patients  who
lso  have  AF,  coagulation  disorders,  atrial  dilatation  and  a
istory  of  systemic  embolism  [54].
It  is  accepted  that  anticoagulation  can  be  avoided  in
he  long-term  in  patients  with  bioprostheses,  sinus  rhythm
nd  no  additional  risk  factors,  but  controversy  remains
bout  antithrombotic  management  in  the  ﬁrst  3  months
fter  surgery  [59]. Previous  studies  indicated  that  the  throm-
oembolic  risk  associated  with  a  prosthesis  was  signiﬁcant
n  the  ﬁrst  3  months  after  the  surgical  operation,  the  risk
eing  almost  eliminated  in  anticoagulated  patients  with  an
ortic  bioprosthesis,  but  remaining  higher  in  patients  with
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 mitral  bioprosthesis  [60,61].  These  embolisms  have  been
inked  to  deposits  of  ﬁbrin  and  platelet  aggregation  on  for-
ign  surfaces,  such  as  Dacron  sutures,  as  well  as  to  a lack
f  endothelialization  [55].  Conversely,  some  more  recent
tudies  suggested  that  there  was  no  beneﬁt  associated  with
nticoagulant  treatment  during  the  90  days  following  an
ortic  valve  replacement  with  a  bioprosthesis  and  no  AF
26,62,63].  This  might  be  explained  by  a  different  mech-
nism,  with  release  of  calcium  microemboli  during  the  peri-
nd  early  postoperative  periods  [64],  which,  however,  are
ften  asymptomatic.  In  addition,  these  calcium  microemboli
o  not  appear  to  be  limited  by  anticoagulant  treatment.
Despite  a  lack  of  ﬁrm  evidence  and  long-term  stud-
es,  current  American  College  of  Cardiology/American  Heart
ssociation  guidelines  recommend  aspirin  use  for  patients
ith  both  aortic  and  mitral  bioprostheses  and  no  AF  or
ther  risk  factors  [65].  American  and  European  societies
onsider  that  the  speciﬁc  risk  caused  by  the  bioprosthe-
is  added  to  the  thromboembolic  risk  of  AF  is  enough
o  facilitate  a  decision  about  effective  anticoagulation
1,26].  These  patients  with  AF  (whether  permanent  or  non-
ermanent,  and  whatever  the  CHA2DS2-VASc  score)  should
lways  receive  long-term  anticoagulation,  currently  with  a
KA,  and  targeting  an  international  normalized  ratio  of  2  to
 [29,66].
Transcatheter  aortic  valve  implantation  (TAVI)  is  actu-
lly  the  insertion  of  a  bioprosthesis  within  an  expandable
tented  structure,  and  has  been  used  increasingly  in  recent
ears  as  an  alternative  to  surgical  aortic  valve  replacement
or  patients  with  AS.  A  combination  of  low-dose  aspirin  and
 thienopyridine  is  usually  prescribed  early  after  TAVI,  fol-
owed  by  aspirin  or  a  thienopyridine  alone  [29].  If  AF  is  also
resent,  one  should  consider  that  the  patient  after  TAVI
as  ‘‘valvular  AF’’  if  one  refers  to  the  most  recent  ESC
uidelines.  The  optimal  antithrombotic  treatment  in  this
etting  is  still  unknown.  Among  TAVI  patients  with  AF  but
ithout  coronary  artery  disease,  oral  anticoagulation  is  rec-
mmended  in  accordance  with  the  recommendations  for  AF
lone  [67].  The  experience  with  patients  receiving  biological
ortic  valve  replacement  suggests  that  oral  anticoagulation
lone  with  VKAs  may  be  sufﬁcient  to  prevent  thrombotic
vents.  Whether  the  addition  of  antiplatelet  therapy  to  oral
nticoagulation  is  required  in  the  context  of  TAVI  with  AF
emains  to  be  determined.  In  AF  patients  undergoing  TAVI,
 combination  of  a  VKA  and/or  aspirin  and/or  or  a  thienopy-
idine  may  be  used  on  an  individual  basis,  particularly  when
oronary  stenting  is  needed,  but  should  be  weighed  against
he  increased  risk  of  bleeding  [29].  There  are  no  data  for
atients  with  TAVI  from  trials  with  the  NOACs.
Overall,  whether  thromboembolic  risk  related  to  bio-
rosthetic  valve  implantation  differs  from  other  forms  of
F  has  not  been  established  with  certainty.  Thromboem-
olism  in  patients  with  bioprosthetic  valves  and  AF  may
resumably  relate  to  both  the  bioprosthetic  valve  and
he  AF  [24].  The  incidence  of  thromboembolism  in  these
atients  was  reported  to  be  in  the  range  of  5—6%/year
68,69],  which  is  not  very  different  from  that  found  in
n  average  age-matched  AF  population  with  risk  factors.
his  may  still  allow  options  for  therapy  with  NOACs  in
F  patients  with  bioprosthesis,  particularly  after  the  third
onth  of  surgery  for  those  with  only  an  aortic  bioprosthesis
70].
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alve repair
atients  undergoing  mitral  valve  repair  have  a  small  risk  of
hromboembolic  events  [71],  with  the  highest  risk  of  throm-
oembolism  occurring  during  the  ﬁrst  year  after  surgery.
uidelines  therefore  recommend  oral  anticoagulation  dur-
ng  months  3—6  post-surgery  [72]. However,  only  limited
ata  are  available  on  the  efﬁcacy  of  warfarin  therapy  early
fter  valve  surgery,  and  the  use  of  short-term  warfarin  in
atients  with  mitral  valve  annuloplasty  is  also  controversial.
t  is  therefore  not  clear  whether  patients  with  AF  in  addition
o  valve  repair  are  markedly  different  from  the  patients  with
o-called  ‘‘non-valvular’’  AF,  and  require  a  speciﬁc  treat-
ent  or  the  avoidance  of  NOACs.  The  North  American  and
uropean  guidelines  have  different  positions  on  this  issue:
he  former  publication  considers  AF  to  be  valvular  while  the
atter  does  not.
uggestions for alternative deﬁnitions and
onclusions
bviously,  we  should  no  longer  consider  the  classiﬁcation
f  AF  as  ‘‘valvular’’  (or  not)  for  the  purpose  of  deﬁning
he  aetiology  of  the  arrhythmia,  but  for  the  determination
f  a  different  risk  of  thromboembolic  events  and  the  need
or  a  speciﬁc  antithrombotic  strategy.  The  term  ‘‘valvular
F’’  and  its  opposite  ‘‘non-valvular  AF’’  may  actually  cause
onfusion,  because  they  should  each  determine  homoge-
eous  groups  of  patients  with  a  similar  pathogenesis  of
hromboembolism,  similar  thromboembolic  risk  and  similar
reatment  needs,  which  is  not  the  case.  In  a  recent  survey
mong  physicians  involved  in  the  prescription  of  anticoagu-
ants  to  AF  patients,  only  57%  of  the  cardiologists  and  68%
f  the  internists  agreed  that  the  current  deﬁnitions  of  non-
alvular  AF  (e.g.  from  guidelines)  were  sufﬁciently  clear
73]. As  none  of  the  objectives  mentioned  above  are  ful-
lled  by  the  current  deﬁnitions,  such  terms  should  be  either
ystematically  deﬁned  (or  reinforced)  or  changed  to  a  more
peciﬁc  terminology.
There  is  a  general  agreement  that  the  risk  of  throm-
oembolism  is  particularly  high  in  AF  accompanying
oderate-to-severe  mitral  stenosis  and  mechanical  pros-
hetic  valves.  As  mitral  stenosis,  with  or  without  other
ssociated  valvular  disease,  is  virtually  always  rheumatic,
he  terms  ‘‘rheumatic  AF’’  and  ‘‘valvular  AF’’  may  be
sed  interchangeably  in  Western  countries.  It  is  not  clear,
owever,  whether  the  pathogenesis  of  thrombosis  in  AF
ccompanying  rheumatic  valve  diseases  (particularly  when
here  is  no  signiﬁcant  mitral  stenosis,  which  may  be  seen  in
on-Western  countries)  is  qualitatively  different  from  that
f  most  common  forms  of  ‘‘non-valvular’’  AF.  Thus,  some
uthors  recently  suggested  that  properly  conducted  trials
f  NOACs  in  patients  with  mitral  stenosis  may  be  justiﬁed
51].
Valvular  heart  diseases,  such  as  mitral  regurgitation,  AS
r  aortic  insufﬁciency,  do  not  result  in  conditions  of  low  ﬂow
n  the  left  atrium,  and  do  not,  apparently,  increase  the  risk
f  thromboembolism  brought  by  AF  per  se.  Post-hoc  anal-
ses  suggest  that  these  conditions,  when  they  present  in  a
oderate  form,  probably  do  not  make  the  thromboembolic
isk  less  responsive  to  NOACs  compared  with  most  forms  of
‘non-valvular’’  AF.
[[
[
[
[
[
[
[
[
[Atrial  ﬁbrillation  and  valve  disease  
The  pathogenesis  of  thrombosis  is  most  likely  to  be  differ-
ent  for  blood  coming  into  contact  with  the  artiﬁcial  surface
of  a  mechanical  prosthetic  valve  compared  with  what  occurs
in  most  other  forms  of  AF  without  concomitant  valvular  dis-
ease.  This  may  explain  the  results  of  the  only  trial  performed
so  far  with  an  NOAC  in  patients  with  a  mechanical  pros-
thetic  valve  (only  a  few  of  whom  had  AF),  where  warfarin
was  more  effective  and  safer  than  the  relatively  high  doses
of  dabigatran  that  were  used  [50].
AF  in  the  presence  of  a  bioprosthetic  heart  valve  or
after  valve  repair  appears  to  have  a  risk  of  thromboem-
bolism  that  is  not  markedly  different  from  other  forms  of
‘‘non-valvular’’  AF.  On  the  basis  of  the  limited  preliminary
evidence  from  trials  with  NOACs,  there  is  no  reported  differ-
ence  in  efﬁcacy  or  safety  compared  with  warfarin,  although
it  is  likely  that  only  a  few  patients  with  a  bioprosthesis  were
actually  included  in  the  ARISTOTLE  and  ENGAGE-AF  trials.
Well-powered  studies  comparing  NOACs  and  VKAs  in  this
setting  would  be  welcome.
De  Caterina  and  Camm  recently  proposed  the  term
‘‘mechanical  and  rheumatic  mitral  valvular  AF’’  (acronym:
MARM-AF)  as  an  accurate  description  of  a  disease  entity
worthy  of  being  kept  separate  from  other  forms  of  AF,  but
with  possible  inner  differences  between  the  two  conditions
[51].  Similarly,  Breithardt  and  Baumgartner  indicated  that
it  would  be  better  if  the  terms  valvular  and  non-valvular  AF
were  abandoned.  Instead,  AF  in  the  presence  of  a  mechan-
ical  valve  and  AF  in  association  with  mitral  stenosis  should
be  highlighted  as  conditions  with  special  needs  for  anticoag-
ulation  [74].  As  long  as  no  new  term  has  been  agreed  upon,
‘‘valvular  AF’’  will  continue  to  be  used,  and  refers  solely  to
patients  with  mitral  stenosis  or  artiﬁcial  heart  valves  (and
valve  repair  in  the  North  American  guidelines  only).  Patients
with  ‘‘non-valvular  AF’’  may  have  other  types  of  valvular
heart  disease.  One  should  emphasize  strongly  that  ‘‘non-
valvular  AF’’  does  not  exclude  patients  with  some  types  of
valvular  heart  disease  from  therapy  with  novel  direct  oral
anticoagulants.
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